Dystrophin involvement in peripheral circadian SRF signalling.
Betts CA. et al, (2021), Life Sci Alliance, 4
Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology.
van Westering TLE. et al, (2020), J Cachexia Sarcopenia Muscle, 11, 578 - 593
A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H. et al, (2019), Hum Mol Genet, 28
Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment.
Gait MJ. et al, (2019), Nucleic Acid Ther, 29, 1 - 12
Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
Betts CA. et al, (2019), Hum Mol Genet, 28, 396 - 406
Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice.
Walter LM. et al, (2018), Hum Mol Genet, 27, 3582 - 3597
Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.
Walter LM. et al, (2018), EBioMedicine, 31, 226 - 242
Profile of circadianly regulated metabolic genes in dystrophic heart
Betts CA. et al, (2018), NEUROMUSCULAR DISORDERS, 28, S19 - S19
PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART
Betts CA. et al, (2018), HEART, 104, A4 - A4
Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
Coenen-Stass AML. et al, (2016), Sci Rep, 6
Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation.
Coenen-Stass AML. et al, (2016), Hum Mol Genet, 25, 3960 - 3974
Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
Coenen-Stass AML. et al, (2015), Sci Rep, 5
How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.
Godfrey C. et al, (2015), Hum Mol Genet, 24, 4225 - 4237
Delivery of therapeutic oligonucleotides with cell penetrating peptides.
Boisguérin P. et al, (2015), Adv Drug Deliv Rev, 87, 52 - 67
Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.
Betts CA. et al, (2015), Sci Rep, 5
Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.
van Westering TLE. et al, (2015), Molecules, 20, 8823 - 8855
Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
Betts CA. et al, (2015), Sci Rep, 5
Delivery of therapeutic oligonucleotides with cell penetrating peptides
(2015), Advanced Drug Delivery Reviews, 87, 52 - 67
Detection and quantification of extracellular microRNAs in murine biofluids.
Roberts TC. et al, (2014), Biol Proced Online, 16